Patents by Inventor Dani P. Bolognesi
Dani P. Bolognesi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7037645Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8+ suppressor molecule, that is produced by the CD8+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of CD8+ cell lines and cell clones that produce that antiviral activity and to the development of assay systems for detection of the antiviral activity. The cell lines, cell clones and assay systems, described herein, may be utilized, e.g., to purify, characterize and clone the CD8+ suppressor molecule. The CD8+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.Type: GrantFiled: February 6, 2002Date of Patent: May 2, 2006Assignee: Duke UniversityInventors: Dani P. Bolognesi, Michael L Greenberg, Simon F Lacey, Georgia D Tomaras, Kent J. Weinhold
-
Publication number: 20030181382Abstract: This invention relates to human immunodeficiency virus (HIV) protein fragments which have antiviral activity, and particularly relates to HIV peptides derived from the HIV transmembrane glycoprotein (gp41) which inhibit HIV-induced cell-cell fusion. This invention further relates to methods for the inhibition of enveloped viral infection, and to methods that modulate biochemical processes which involve coiled coil peptide interactions.Type: ApplicationFiled: April 15, 2003Publication date: September 25, 2003Applicant: Duke UniversityInventors: Carl T. Wild, Thomas J. Matthews, Dani P. Bolognesi
-
Patent number: 6586174Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8+ suppressor molecule, that is produced by the CD8+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of clonal CD8+ cells lines that produce the antiviral activity and the development of an assay system for detection of the antiviral activity. The clonal cell lines and the assay system, described herein, may be utilized to purify, characterize and clone the CD8+ suppressor molecule. The CD8+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.Type: GrantFiled: November 29, 1999Date of Patent: July 1, 2003Assignee: Duke UniversityInventors: Dani P. Bolognesi, Chin-Ho Chen, Michael Greenberg, Kent Weinhold, Simon F. Lacey
-
Patent number: 6573078Abstract: This invention relates to human immunodeficiency virus (HIV) protein fragments which have antiviral activity, and particularly relates to HIV peptides derived from the HIV transmembrane glycoprotein (gp41) which inhibit HIV-induced cell-cell fusion. This invention further relates to methods for the inhibition of enveloped viral infection, and to methods that modulate biochemical processes which involve coiled coil peptide interactions.Type: GrantFiled: June 2, 1995Date of Patent: June 3, 2003Assignee: Duke UniversityInventors: Carl T. Wild, Thomas J. Matthews, Dani P. Bolognesi
-
Patent number: 6528308Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8+ suppressor molecule, that is produced by the CD8+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of CD8+ cell lines and cell clones that produce that antiviral activity and to the development of assay systems for detection of the antiviral activity. The cell lines, cell clones and assay systems, described herein, may be utilized, e.g., to purify, characterize and clone the CD8+ suppressor molecule. The CD8+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.Type: GrantFiled: March 16, 2000Date of Patent: March 4, 2003Assignee: Duke UniversityInventors: Dani P. Bolognesi, Michael L. Greenberg, Simon F. Lacey, Georgia D. Tomaras, Kent J. Weinhold
-
Publication number: 20020102538Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8+ suppressor molecule, that is produced by the CD8+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of CD8+ cell lines and cell clones that produce that antiviral activity and to the development of assay systems for detection of the antiviral activity. The cell lines, cell clones and assay systems, described herein, may be utilized, e.g., to purify, characterize and clone the CD8+ suppressor molecule. The CD8+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.Type: ApplicationFiled: February 6, 2002Publication date: August 1, 2002Applicant: Duke UniversityInventors: Dani P. Bolognesi, Michael L. Greenberg, Simon F. Lacey, Georgia D. Tomaras, Kent J. Weinhold
-
Patent number: 6290963Abstract: Native and recombinant peptides which elicit anti-HIV immune response are provided.Type: GrantFiled: February 23, 1989Date of Patent: September 18, 2001Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Peter J. Fischinger, Flossie Wong-Stall, Robert C. Gallo, Thomas J. Matthews, Dani P. Bolognesi, Gerard W. Robey, Kai Krohn, Annamarie Ranki
-
Patent number: 5994054Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8.sup.+ suppressor molecule, that is produced by the CD8.sup.+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of clonal CD8.sup.+ cells lines that produce the antiviral activity and the development of an assay system for detection of the antiviral activity. The clonal cell lines and the assay system, described herein, may be utilized to purify, characterize and clone the CD8.sup.+ suppressor molecule. The CD8.sup.+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.Type: GrantFiled: June 7, 1995Date of Patent: November 30, 1999Assignee: Duke University Medical CenterInventors: Dani P. Bolognesi, Chin-Ho Chen, Michael Greenberg, Kent Weinhold, Simon F. Lacey
-
Patent number: 5861490Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8.sup.+ suppressor molecule, that is produced by the CD8.sup.+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of clonal CD8.sup.+ cells lines that produce the antiviral activity and the development of an assay system for detection of the antiviral activity. The clonal cell lines and the assay system, described herein, may be utilized to purify, characterize and clone the CD8.sup.+ suppressor molecule. The CD8.sup.+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.Type: GrantFiled: June 6, 1995Date of Patent: January 19, 1999Assignee: Duke University Medical CenterInventors: Dani P. Bolognesi, Chin-Ho Chen, Michael Greenberg, Kent Weinhold, Simon F. Lacey
-
Patent number: 5814519Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8.sup.+ suppressor molecule, that is produced by the CD8.sup.+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of clonal CD8.sup.+ cells lines that produce the antiviral activity and the development of an assay system for detection of the antiviral activity. The clonal cell lines and the assay system, described herein, may be utilized to purify, characterize and clone the CD8.sup.+ suppressor molecule. The CD8.sup.+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.Type: GrantFiled: June 7, 1995Date of Patent: September 29, 1998Assignee: Duke University Mdeical CenterInventors: Dani P. Bolognesi, Chin-Ho Chen, Michael Greenberg, Kent Weinhold, Simon F. Lacey
-
Patent number: 5656480Abstract: This invention relates to human immunodeficiency virus (HIV) protein fragments which have antiviral activity, and particularly relates to HIV peptides derived from the HIV transmembrane glycoprotein (gp41) which inhibit HIV-induced cell-cell fusion. This invention further relates to methods for the inhibition of enveloped viral infection, and to methods that modulate biochemical processes which involve coiled coil peptide interactions.Type: GrantFiled: January 27, 1995Date of Patent: August 12, 1997Assignee: Duke UniversityInventors: Carl T. Wild, Thomas J. Matthews, Dani P. Bolognesi
-
Patent number: 5627023Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8 suppressor molecule, that is produced by the CD8 subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of vital transcription. The invention relates to isolation of clonal CD8 cells lines that produce the antiviral activity and the development of an assay system for detection of the antiviral activity. The clonal cell lines and the assay system, described herein, may be utilized to purify, characterize and clone the CD8 suppressor molecule. The CD8 suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.Type: GrantFiled: March 29, 1993Date of Patent: May 6, 1997Assignee: Duke UniversityInventors: Dani P. Bolognesi, Chin-Ho Chen, Michael L. Greenberg, Kent Weinhold
-
Patent number: 5464933Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP-178 (SEQ ID:1) ptides corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP-178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.Type: GrantFiled: June 7, 1993Date of Patent: November 7, 1995Assignee: Duke UniversityInventors: Dani P. Bolognesi, Thomas J. Matthews, Carl T. Wild